Di Lonardo A, Campo M S, Venuti A, Marcante M L
Laboratory of Virology, CRS-Regina Elena Institute for Cancer Research, Rome, Italy.
J Med Virol. 1994 Aug;43(4):357-61. doi: 10.1002/jmv.1890430407.
The serological response to human papillomavirus type 16 (HPV16) E6, E7, and L1 proteins was investigated in Italian patients with cervical cancer, cervical intraepithelial neoplasia (CIN), flat cervical warts, condylomas, and in healthy individuals. Bacterially expressed beta-galactosidase fusion proteins were purified and used as antigen in Western blot assays. The HPV16 DNA status was also determined in most of the women. The incidence of antibody response to E6 and E7 proteins was higher in cervical cancer than in CIN patients. No variation of antibody titre against E6 was observed in the cervical cancer patients, while one patient in an advanced stage of disease displayed very high levels of E7 antibodies. High seroprevalence to both E6 and L1 was observed in patients with genital condylomas, but this may be due to cross-reactivity between HPV6 or 11 antibodies and the experimental HPV16 antigens. Antibodies to L1 were detected in control women, suggesting that HPV infection is widespread. The data obtained in this study are in agreement with previous findings in other countries.
在意大利的宫颈癌患者、宫颈上皮内瘤变（CIN）患者、扁平宫颈湿疣患者、尖锐湿疣患者以及健康个体中，对人乳头瘤病毒16型（HPV16）E6、E7和L1蛋白的血清学反应进行了研究。细菌表达的β-半乳糖苷酶融合蛋白经纯化后用作蛋白质印迹分析中的抗原。大多数女性的HPV16 DNA状态也得以确定。宫颈癌患者中对E6和E7蛋白的抗体反应发生率高于CIN患者。宫颈癌患者中未观察到针对E6的抗体滴度变化，而一名疾病晚期患者显示出非常高水平的E7抗体。尖锐湿疣患者中观察到对E6和L1的高血清阳性率，但这可能是由于HPV6或11抗体与实验性HPV16抗原之间的交叉反应所致。在对照女性中检测到了针对L1的抗体，表示HPV感染很普遍。本研究获得的数据与其他国家先前的研究结果一致。
